Esperion Therapeutics Inc (NAS:ESPR)
$ 2.8 0.33 (13.36%) Market Cap: 530.49 Mil Enterprise Value: 572.87 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 55/100

Esperion Therapeutics Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript

Nov 12, 2019 / 08:50PM GMT
Release Date Price: $40 (+3.31%)
Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

So welcome. I'm Marty Auster. I'm the lead SMID cap biotech analyst at Crédit Suisse, joined now by Esperion Therapeutics. We have CEO, Tim Mayleben; and the Chief Commercial Officer, Mark Glickman. And I wish we could do this more than once a year, Tim.

Timothy M. Mayleben
Esperion Therapeutics, Inc. - President, CEO & Director

So do all of our assembled panelists.

Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Exactly. Thanks, everyone, for joining us, and thanks for coming. So let's talk about Esperion. I'm sure you'd like to kind of just maybe provide just a little overview of kind of where you're at? Obviously, you've had a pretty busy year since we saw you last November.

Timothy M. Mayleben;Martin Douglas Auster<
Esperion Therapeutics, Inc. - President, CEO & Director

Yes.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot